Previously, our group has demonstrated that OPN5 treatment reduced T-cell dysfunction in CLL [24]; however, we wanted to expand this characterization, especially considering the decreased T-cell suppressive activity of MDSCs in OPN5-treated mice. This evidence concerns the gene OPN5 and B-cell chronic lymphocytic leukemia.